Afatinib Recruiting Phase 4 Trials for ErbB Receptors / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02514174Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older